|
Hi Michka
The problem is that even though 40% is a massive reduction in the rate of recurrence, there are still going to be some women who don't benefit at all.
I had neoadjuvant FEC and it didn't seem to have worked at all and I had severe problems with it. I figure that the taxotere I had after surgery must have done something because I haven't had a recurrence over four years after diagnosis and my prospects were pretty dire and I found taxotere really easy. I had herceptin, but fifteen months after I finished treatment because of when the trial came out.
I guess the good news is that a newly diagnosed her2 positive patient can be pretty confident that the treatments will be worth it.
|